Centessa Pharmaceuticals (CNTA) Cash from Operations (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Cash from Operations of 72224000.0 for Q1 2026, down 26.16% year-over-year from 97817145.45 in Q1 2025, and down 29.42% on a QoQ basis from 55807000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Cash from Operations data on file, last reported at 72224000.0 in Q1 2026.
- Quarterly Cash from Operations fell 26.16% year-over-year to 72224000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 208795000.0 (down 28.87% YoY) and the FY2025 annual result came in at 193817000.0, down 36.44% from the prior year.
- Cash from Operations declined to 72224000.0 in Q1 2026 per CNTA's latest filing, from 55807000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 21389000.0 in Q3 2024 and bottomed at 72224000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 44062000.0 (2023), against an average of 45234352.94.
- The widest annual swing landed in 2022, when Cash from Operations tumbled 329.88%; it then jumped 44.67% in 2025.
- Tracing CNTA's Cash from Operations over 5 years: stood at 51564000.0 in 2022, then soared by 39.78% to 31050000.0 in 2023, then slumped by 37.84% to 42800000.0 in 2024, then sank by 30.39% to 55807000.0 in 2025, then decreased by 29.42% to 72224000.0 in 2026.
- Per Business Quant, the three latest CNTA Cash from Operations figures stand at 72224000.0 (Q1 2026), 55807000.0 (Q4 2025), and 58312000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -72.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.22 Mn |
| Mar 31, 2026 | -72.22 Mn |
| Dec 31, 2025 | -55.81 Mn |
| Dec 31, 2025 | -55.81 Mn |
| Sep 30, 2025 | -58.31 Mn |
| Sep 30, 2025 | -58.31 Mn |
| Jun 30, 2025 | -22.45 Mn |
| Jun 30, 2025 | -22.45 Mn |
| Mar 31, 2025 | -57.25 Mn |
| Mar 31, 2025 | -57.25 Mn |
| Dec 31, 2024 | -42.80 Mn |
| Dec 31, 2024 | -42.80 Mn |
| Sep 30, 2024 | -21.39 Mn |
| Sep 30, 2024 | -21.39 Mn |
| Jun 30, 2024 | -40.58 Mn |
| Jun 30, 2024 | -40.58 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | -31.05 Mn |
| Dec 31, 2023 | -31.05 Mn |
| Sep 30, 2023 | -37.39 Mn |
| Sep 30, 2023 | -37.39 Mn |
| Jun 30, 2023 | -44.06 Mn |
| Jun 30, 2023 | -44.06 Mn |
| Mar 31, 2023 | -47.84 Mn |
| Mar 31, 2023 | -47.84 Mn |
| Dec 31, 2022 | -51.56 Mn |
| Dec 31, 2022 | -51.56 Mn |
| Sep 30, 2022 | -39.09 Mn |
| Sep 30, 2022 | -39.09 Mn |
| Jun 30, 2022 | -59.88 Mn |
| Jun 30, 2022 | -59.88 Mn |
| Mar 31, 2022 | -50.02 Mn |
| Mar 31, 2022 | -50.02 Mn |
| Dec 31, 2021 | -56.43 Mn |
| Dec 31, 2021 | -56.43 Mn |
| Sep 30, 2021 | -33.17 Mn |
| Sep 30, 2021 | -33.17 Mn |
| Jun 30, 2021 | -33.88 Mn |
| Jun 30, 2021 | -33.88 Mn |
| Mar 31, 2021 | -11.64 Mn |
| Mar 31, 2021 | -11.64 Mn |
| Dec 31, 2020 | -3.28 Mn |
| Dec 31, 2020 | -3.28 Mn |
| Sep 30, 2020 | -1.90 Mn |
| Sep 30, 2020 | -1.90 Mn |